Suchergebnisse - "Zweegman, Sonja"

PubPharm (29)

1

Monoclonal Antibodies in the Treatment of Multiple Myeloma

enthalten in: Hematology/oncology clinics of North America | 2024

von van de Donk, N. | Zweegman, S.

2

Cost-effectiveness : maximizing impact by meticulous data

enthalten in: Blood | 2022

von Blommestein, H. | Zweegman, S.

CommentOn: Blood. 2022 Aug 11;140(6):594-607. - PMID 35580269

3

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA

enthalten in: Leukemia | 2022

von Facon, T. | Cook, G. | Usmani, S. | +25

4

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma

enthalten in: Blood advances | 2021

von Frerichs, K. | Minnema, M. | Levin, M. | +11

5

Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies : the laboratory solution to eliminate interference

enthalten in: Clinical chemistry and laboratory medicine | 2021

von Noori, S. | Verkleij, C. | Zajec, M. | +8

6

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Moreau, P. | Hulin, C. | Perrot, A. | +49

CommentIn: Nat Rev Clin Oncol. 2021 Nov;18(11):676. - PMID 34545220

7

Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma : The Hovon 143 Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Stege, C. | Nasserinejad, K. | van der Spek, E. | +22

8

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO) : an open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Dimopoulos, M. | Terpos, E. | Boccadoro, M. | +72

9

Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma : matching-adjusted indirect comparison

enthalten in: Immunotherapy | 2021

von Moreau, P. | Hebraud, B. | Facon, T. | +23

10

Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA) : health-related quality of life outcomes of a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Haematology | 2020

von Roussel, M. | Moreau, P. | Hebraud, B. | +18